Pharming Group N.V. (PHARM.AS) Stock Analysis & Winston Score

Pharming Group is a Dutch biotechnology company that makes medicines for rare, life-threatening diseases. Its main product is RUCONEST, a treatment for hereditary angioedema (HAE), a genetic condition that causes sudden and dangerous swelling attacks. The company sells primarily to hospitals and specialist physicians in the United States and Europe. Pharming earns revenue by selling its medicines directly to healthcare providers and through distribution partners, with the U.S. market generating the majority of sales. The company has a meaningful competitive advantage because RUCONEST is one of only a few approved treatments for HAE, and developing medicines for rare diseases takes years and significant regulatory hurdles to replicate. However, Pharming is a small company with a narrow product portfolio, meaning its financial performance is heavily dependent on a single drug — and competition from other HAE therapies, including newer preventive treatments, remains a key ongoing risk to its market share and growth.